Revenues and earnings to improve for companies with low forex liabilities and no forward cover.
The rap from both the US and UK drug regulators, including the latest one from the latter, has hit the scrip.
With sales of over Rs 12,240 crore in nine months of the current financial year, it is ahead of Rs 11,580 crore recorded by Lupin but behind Sun Pharma, which reported Rs 19,350 crore sales.
Increased price control over branded generic medicines has affected its profitability
Analysts are divided on the deal valuations. Some say Torrent could have bargained harder, as Sanofi, among others, passed it over.
Cipla, though late in changing its strategy for international markets, has in recent years taken an inorganic route for expansion.
Expectations of strong results, consistent performance and investors preference for stocks in the defensive space help the sector outshine broader markets.
According to industry estimates, the sector's revenue would increase eight-10 per cent in 2013-14, against 12 per cent in 2012-13.
The industry feels that prices of active pharmaceutical ingredients (APIs) can go up in the range of 5-15 per cent.
The finance ministry is resisting pressure from other departments to cap foreign ownership of domestic drugmakers, fearing such a move would discourage potential investors, a senior ministry source said.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances